U.S. patent application number 10/607882 was filed with the patent office on 2004-01-01 for methods for making recombinant proteins using apoptosis inhibitors.
This patent application is currently assigned to Genentech, Inc.. Invention is credited to Dixit, Vishva, Goor, Jana van de, Hamilton, Robert W..
Application Number | 20040002139 10/607882 |
Document ID | / |
Family ID | 22558684 |
Filed Date | 2004-01-01 |
United States Patent
Application |
20040002139 |
Kind Code |
A1 |
Dixit, Vishva ; et
al. |
January 1, 2004 |
Methods for making recombinant proteins using apoptosis
inhibitors
Abstract
The invention provided improved methods of making and producing
recombinant proteins in in vitro cultures of host cells using
apoptosis inhibitors. The use of one or more apoptosis inhibitors
in the methods can reduce apoptosis in the cell cultures and
markedly improve yield of the desired recombinant proteins.
Inventors: |
Dixit, Vishva; (Los Altos
Hills, CA) ; Hamilton, Robert W.; (San Carlos,
CA) ; Goor, Jana van de; (Foster City, CA) |
Correspondence
Address: |
Genentech, Inc.
Attn: Diane L. Marschang
1 DNA Way
South San Francisco
CA
94080-4990
US
|
Assignee: |
Genentech, Inc.
|
Family ID: |
22558684 |
Appl. No.: |
10/607882 |
Filed: |
June 27, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10607882 |
Jun 27, 2003 |
|
|
|
09668924 |
Sep 25, 2000 |
|
|
|
6586206 |
|
|
|
|
60156232 |
Sep 27, 1999 |
|
|
|
Current U.S.
Class: |
435/69.2 ;
435/184; 435/320.1; 435/325; 536/23.2 |
Current CPC
Class: |
C12N 2710/14022
20130101; C12N 7/00 20130101; C12N 1/38 20130101; C12N 15/67
20130101; C12N 2500/36 20130101; C12N 2510/02 20130101; C12N
2501/48 20130101; A61P 43/00 20180101; C07K 14/005 20130101; C07K
14/8139 20130101; C12N 2500/92 20130101; C12P 21/02 20130101; C12N
9/6475 20130101 |
Class at
Publication: |
435/69.2 ;
435/184; 435/320.1; 435/325; 536/23.2 |
International
Class: |
C12P 021/02; C12N
005/06; C07H 021/04; C12N 009/99 |
Claims
What is claimed is:
1. A method of making recombinant proteins using one or more
apoptosis inhibitors, comprising the steps of: (a) providing a
vector comprising a gene encoding an apoptosis inhibitor, (b)
providing a vector comprising a gene encoding a protein of
interest, (c) providing a host cell, (d) transforming or
transfecting the host cell with the vector of steps (a) and (b),
(e) providing cell culture media, (f) culturing the transformed or
transfected host cell in the cell culture media under conditions
sufficient for expression of the protein of interest and the
apoptosis inhibitor, and optionally (g) recovering or purifying the
protein of interest from the host cell and/or the cell culture
media.
2. The method of claim 1 further comprising the step of admixing an
additional apoptosis inhibitor into the cell culture media in steps
(e) or (f).
3. The method of claim 1 wherein the vector of step (a) and the
vector of step (b) are the same vector.
4. The method of claim 1 wherein the vectors of steps (a) and (b)
are two separate vectors.
5. The method of claim 4 wherein the vectors of steps (a) and (b)
comprise different antibiotic resistance selection markers.
6. The method of claim 1 wherein the host cell is a CHO cell.
7. The method of claim 1 wherein the host cell is E. coli.
8. The method of claim 1 wherein the apoptosis inhibitor gene of
step (a) encodes for the caspase-9 dominant negative protein or
baculovirus p35.
9. The method of claim 1 wherein the host cells are cultured under
conditions for transient expression of the protein of interest.
10. The method of claim 1 wherein the protein of interest comprises
a protein which is capable of inducing apoptosis in a mammalian or
non-mammalian cell.
11. The method of claim 1 wherein said cell culture media is
serum-free media.
12. The method of claim 1 wherein said cell culture media comprises
butyrate.
13. The method of claim 1 wherein after step (f), the host cell(s)
and/or cell culture media is frozen and subsequently thawed.
14. A method of making recombinant proteins using one or more
apoptosis inhibitors, comprising the steps of: (a) providing a
vector comprising a gene encoding a protein of interest, (b)
providing a host cell comprising a gene encoding an apoptosis
inhibitor, (c) transforming or transfecting the host cell with the
vector of step (a), (d) providing cell culture media, (e) culturing
the transformed or transfected host cell in the cell culture media
under conditions sufficient for expression of the protein of
interest and the apoptosis inhibitor, and optionally (f) recovering
or purifying the protein of interest from the host cell and/or cell
culture media.
15. The method of claim 14 wherein the gene encoding the apoptosis
inhibitor is stably integrated into the genome of the host
cell.
16. The method of claim 14 further comprising the step of admixing
an additional apoptosis inhibitor molecule into the cell culture
media in steps (d) or (e).
17. The method of claim 14 wherein the host cell is a CHO cell.
18. The method of claim 14 wherein the host cell is E. coli.
19. The method of claim 14 wherein the apoptosis inhibitor gene of
step (b) encodes for the caspase-9 dominant negative protein or
baculovirus p35.
20. The method of claim 14 wherein said cell culture media
comprises butyrate.
21. The method of claim 14 wherein after step (e), the host cell(s)
and/or cell culture media is frozen and subsequently thawed.
22. A method of making recombinant proteins using one or more
apoptosis inhibitors, comprising-the steps of: a) providing a
vector comprising a gene encoding a protein of interest, b)
providing a host cell, c) transforming or transfecting the host
cell with the vector of step (a), d) providing cell culture media,
e) providing an apoptosis inhibitor, f) admixing the apoptosis
inhibitor into the cell culture media, g) culturing the host cell
in the cell culture media under conditions sufficient for
expression of the protein of interest, and optionally h) recovering
or purifying the protein of interest from the host cell and/or the
cell culture media.
23. The method of claim 22 wherein the host cell is a CHO cell.
24. The method of claim 22 wherein the apoptosis inhibitor
comprises an organic or inorganic molecule.
25. The method of claim 24 wherein the apoptosis inhibitor
comprises z-VAD-fmk.
26. The method of claim 22 wherein after step (g), the host cell(s)
and/or cell culture media is frozen and subsequently thawed.
27. A method of increasing yield of a protein of interest in a cell
culture, comprising the steps of: (a) providing a vector comprising
a gene encoding an apoptosis inhibitor selected from the group
consisting of caspase-9 dominant negative protein and baculovirus
p35, (b) providing a vector comprising a gene encoding a protein of
interest, (c) providing a host cell, (d) transforming or
transfecting the host cell with the vector of steps (a) and (b),
(e) providing cell culture media, (f) culturing the transformed or
transfected host cell in the cell culture media under conditions
sufficient for expression of the protein of interest and an amount
of the apoptosis inhibitor which is effective in increasing yield
of the protein of interest, and optionally (g) recovering or
purifying the protein of interest from the host cell and/or the
cell culture media.
28. The method of claim 27 wherein said host cell is a CHO
cell.
29. The method of claim 27 wherein said cell culture media is
serum-free media.
30. The method of claim 27 wherein after step (f), the host cell(s)
and/or cell culture media is frozen and subsequently thawed.
31. A method of prolonging host cell viability in a cell culture,
comprising the steps of: (a) providing a vector comprising a gene
encoding an apoptosis inhibitor selected from the group consisting
of caspase-9 dominant negative protein and baculovirus p35, (b)
providing a vector comprising a gene encoding a protein of
interest, (c) providing a host cell, (d) transforming or
transfecting the host cell with the vector of steps (a) and (b),
(e) providing cell culture media, (f) culturing the transformed or
transfected host cell in the cell culture media under conditions
sufficient for expression of the protein of interest and an amount
of the apoptosis inhibitor which is effective for prolonging
viability of the host cells in the cell culture, and optionally (g)
recovering or purifying the protein of interest from the host cell
and/or the cell culture media.
32. The method of claim 31 wherein the vector comprising the gene
encoding the apoptosis inhibitor includes an inducible
promoter.
33. A composition of matter comprising a protein of interest
produced in accordance with the method of claim 1.
34. A composition of matter comprising a protein of interest
produced in accordance with the method of claim 14.
35. A composition of matter comprising a protein of interest
produced in accordance with the method of claim 22.
36. A composition of matter comprising a protein of interest
produced in accordance with the method of claim 27.
37. A composition of matter comprising a protein of interest
produced in accordance with the method of claim 31.
Description
RELATED APPLICATIONS
[0001] This is a non-provisional application claiming priority
under Section 119(e) to provisional application No. 60/156,232,
filed Sep. 27, 1999, the contents of which are incorporated herein
by reference.
FIELD OF THE INVENTION
[0002] The present invention relates generally to improved methods
of making recombinant proteins using one or more apoptosis
inhibitors.
BACKGROUND OF THE INVENTION
[0003] Control of cell numbers in mammals is believed to be
determined, in part, by a balance between cell proliferation and
cell death. One form of cell death, sometimes referred to as
necrotic cell death, is typically characterized as a pathologic
form of cell death resulting from some trauma or cellular injury.
In contrast, there is another, "physiologic" form of cell death
which usually proceeds in an orderly or controlled manner. This
orderly or controlled form of cell death is often referred to as
"apoptosis" [see, e.g., Barr et al., Bio/Technology, 12:487-493
(1994); Steller et al., Science, 267:1445-1449 (1995)]. Apoptotic
cell death naturally occurs in many physiological processes,
including embryonic development and clonal selection in the immune
system [Itoh et al., Cell, 66:233-243 (1991)].
[0004] Control of cell numbers in cell culture and bioreactors is
also a balance between cell proliferation and cell death. There
have been reports in the literature indicating cell death in
bioreactors can be an apoptotic process [Suzuki E., et al.,
Cytotechnology, 23:55-59 (1997); Al-Rubeai, M. and Singh R. P,
Curr. Opin. Biotech, 9:152-156 (1998)]. It has been described that
the apoptotic process may be induced by nutrient deprivation
[Franek F. and Chldkova-{haeck over (S)}rmkov K., Cytotechnology,
18:113-117 (1995); Mercille S. and Massie B., Biotechnol. Bioeng.,
44:1140-1154 (1994); Singh R. P., et al., Biotechnol. Bioeng.,
44:720-726 (1994)], serum deprivation [Singh R. P., et al.,
Biotechnol. Bioeng., 44:720-726 (1994); Zanghi A., et al., Biotech.
Bioeng., 64:108-119 (1999)] or other controllable parameters of
cell culture in bioreactors, but is not controlled fully because of
bioreactor mechanics, a lack of full understanding of necessary
culture parameters, or other undetermined causes.
[0005] As presently understood, the apoptosis or cell death program
contains at least three important elements activators, inhibitors,
and effectors; in C. elegans, these elements are encoded
respectively by three genes, Ced-4, Ced-9 and Ced-3 [Steller,
Science, 267:1445 (1995); Chinnaiyan et al., Science, 275:1122-1126
(1997); Wang et al., Cell, 90:1-20 (1997)]. Two of the TNFR family
members, TNFR1 and Fas/Apo1 (CD95), can activate apoptotic cell
death [Chinnaiyan and Dixit, Current Biology 6:555-562 (1996);
Fraser and Evan, Cell; 85:781-784 (1996)]. TNFR1 is also known to
mediate activation of the transcription factor, NF-KB [Tartaglia et
al., Cell, 74:845-853 (1993); Hsu et al., Cell, 84:299-308 (1996)].
In addition to some ECD homology, these two receptors share
homology in their intracellular domain (ICD) in an oligomerization
interface known as the death domain [Tartaglia et al., supra;
Nagata, Cell, 88:355 (1997)]. Death domains are also found in
several metazoan proteins that regulate apoptosis, namely, the
Drosophila protein, Reaper, and the mammalian proteins referred to
as FADD/MORT1, TRADD, and RIP [Cleaveland and Ihle, Cell,
81:479-482 (1995)].
[0006] Upon ligand binding and receptor clustering, TNFR1 and CD95
are believed to recruit FADD into a death-inducing signaling
complex. CD95 purportedly binds FADD directly, while TNFR1 binds
FADD indirectly via TRADD [Chinnaiyan et al., Cell, 81:505-512
(1995); Boldin et al., J. Biol. Chem., 270:387-391 (1995); Hsu et
al., supra; Chinnaiyan et al., J. Biol. Chem., 271:4961-4965
(1996)]. It has been reported that FADD serves as an adaptor
protein which recruits the Ced-3-related protease, MACH-alpha/FLICE
(caspase 8), into the death signaling complex [Boldin et al., Cell,
85:803-815 (1996); Muzio et al., Cell, 85:817-827 (1996)].
MACH-alpha/FLICE appears to be the trigger that sets off a cascade
of apoptotic proteases, including the interleukin-1beta converting
enzyme (ICE) and CPP32/Yama, which may execute some critical
aspects of the cell death programme [Fraser and Evan, supra].
[0007] It was recently disclosed that programmed cell death
involves the activity of members of a family of cysteine proteases
related to the C. elegans cell death gene, ced-3, and to the
mammalian IL-1-converting enzyme, ICE. The activity of the ICE and
CPP32/Yama proteases can be inhibited by the product of the cowpox
virus gene, crmA [Ray et al., Cell, 69:597-604 (1992); Tewari et
al., Cell, 81:801-809 (1995)]. Recent studies show that CrmA can
inhibit TNFR1- and CD95-induced cell death [Enari et al., Nature,
375:78-81 (1995); Tewari et al., J. Biol. Chem., 270:3255-3260
(1995)].
[0008] As reviewed recently by Tewari et al., TNFR1, TNFR2 and CD40
modulate the expression of proinflammatory and costimulatory
cytokines, cytokine receptors, and cell adhesion molecules through
activation of the transcription factor, NF-KB [Tewari et al., Curr.
Op. Genet. Develop., 6:39-44 (1996)]. NF-KB is the prototype of a
family of dimeric transcription factors whose subunits contain
conserved Rel regions [Verma et al., Genes Develop., 9:2723-2735
(1996); Baldwin, Ann. Rev. Immunol., 14:649-681 (1996)]. In its
latent form, NF-KB is complexed with members of the IKB inhibitor
family; upon inactivation of the IKB in response to certain
stimuli, released NF-KB translocates to the nucleus where it binds
to specific DNA sequences and activates gene transcription.
[0009] For recent reviews of such signaling pathways, see, e.g.,
Ashkenazi et al., Science, 281:1305-1308 (1998); Nagata, Cell,
88:355-365 (1997).
[0010] To date, there have been conflicting reports as to the
effects of caspase inhibitors and expression of anti-apoptotic
genes on cultured recombinant cells. For instance, Murray et al.,
Biotech. Bioeng., 51:298-304 (1996) describe that overexpression of
bcl-2 in NSO myeloma cells failed to affect the decline phase
characteristics of the cultured cells. Other investigators have
found, in contrast, that bcl-2 can be effective in preventing
different cell lines from death under cell-culture conditions [see,
e.g., Itoh et al., Biotechnol. Bioeng., 48:118-122 (1995);
Mastrangelo et al., TIBTECH, 16:88-95 (1998); Simpson et al.,
Biotechnol. Bioeng., 54:1-16 (1997); Singh et al., Biotechnol.
Bioeng., 52:166-175 (1996)]. Goswami et al., Biotechnol. Bioeng.,
62:632-640 (1999) report that they found that the caspase
inhibitor, z-VAD-fmk, was unable to substantially extend the life
of a serum-free culture of CHO cells.
SUMMARY OF THE INVENTION
[0011] The present invention is based on Applicants' findings that
employing one or more apoptosis inhibitor(s) in recombinant cell
culturing and protein production can markedly reduce apoptosis in
the cell culture and improve recombinant protein production
techniques. The methods disclosed in present application are
useful, for example, in prolonging cell viability in cell cultures
or improving or enhancing yield of the recombinant proteins from
the cell cultures. Further improvements provided by the invention
are described in detail below.
[0012] In one embodiment, the invention provides a method of making
recombinant proteins using one or more apoptosis inhibitors. The
method includes the steps of (a) providing a vector comprising a
gene encoding an apoptosis inhibitor, (b) providing a vector
comprising a gene encoding a protein of interest, (c) providing a
host cell, (d) transforming or transfecting the host cell with the
vectors referred to in steps (a) and (b), (e) providing cell
culture media, (f) culturing the transformed or transfected host
cell(s) in the culture media under conditions sufficient to express
the protein of interest and the apoptosis inhibitor, and (g)
recovering or purifying the protein of interest from the host cells
and/or the cell culture media. Optionally, the method further
includes the step of admixing an additional apoptosis inhibitor
into the culture media. In the method, the respective genes
encoding the apoptosis inhibitor and the protein of interest may be
inserted into a single vector (e.g., co-transfected in a single
vector), or alternatively, be inserted into two separate vectors.
Preferably, the respective genes encoding the apoptosis inhibitor
and the protein of interest are inserted into two separate vectors,
each vector having a different type of selection marker from the
other vector. Optionally, the method provides for transient
expression of the protein of interest and stable or transient
expression of the apoptosis inhibitor. Optionally, the gene
encoding the apoptosis inhibitor comprises a gene encoding the
caspase-9-DN protein or baculovirus p35.
[0013] In another embodiment, the method includes the steps of (a)
providing a vector comprising a gene encoding a protein of
interest, (b) providing a host cell comprising DNA encoding an
apoptosis inhibitor, (c) transforming or transfecting the host
cell(s) with the vector referred to in step (a), (d) providing cell
culture media, (e) culturing,the transformed or transfected host
cell(s) in the culture media under conditions sufficient to express
the protein of interest and the apoptosis inhibitor, and (f)
recovering or purifying the protein of interest from the host cells
and/or cell culture media. Optionally, the gene encoding the
apoptosis inhibitor may be stably integrated into the genome of the
host cell. Optionally, the method includes the further step of
admixing an additional apoptosis inhibitor molecule into the
culture media. Optionally, the method provides for transient
expression of the protein of interest and stable or transient
expression of the apoptosis inhibitor.
[0014] In another embodiment, the method includes the steps of (a)
providing a vector comprising a gene encoding a protein of
interest, (b) providing a host cell, (c) transforming or
transfecting the host cell with the vector referred to in step (a),
(d) providing cell culture media, (e) providing an apoptosis
inhibitor, (f) admixing the apoptosis inhibitor into the culture
media, (g) culturing the host cell(s) in the culture media under
conditions sufficient to express the protein of interest, and (h)
recovering or purifying the protein of interest from the host cells
and/or the cell culture media. Optionally, the method provides for
transient expression of the protein of interest.
[0015] In another embodiment, the method includes the steps of (a)
providing a vector comprising a gene encoding an apoptosis
inhibitor, (b) providing a vector comprising a gene encoding a
protein of interest, (c) providing a host cell, (d) transforming or
transfecting the host cell with the vectors referred to in steps
(a) and (b), (e) providing cell culture media, (f) culturing the
transformed or transfected host cell(s) in the culture media under
conditions sufficient to express the protein of interest and the
apoptosis inhibitor, and (g) freezing and subsequently thawing the
host cells and/or the cell culture media. Optionally, the method
further includes the step of admixing an additional apoptosis
inhibitor into the culture media in steps (e) or (f). In the
method, the respective genes encoding the apoptosis inhibitor and
the protein of interest may be inserted into a single vector, or
alternatively, be inserted into two separate vectors. Preferably,
the respective genes encoding the apoptosis inhibitor and the
protein of interest are inserted into two separate vectors, each
vector having a different type of selection marker from the other
vector. Optionally, the method provides for transient expression of
the protein of interest and stable or transient expression of the
apoptosis inhibitor.
[0016] In another embodiment, the method includes the steps of (a)
providing a vector comprising a gene encoding a protein of
interest, (b) providing a host cell comprising DNA encoding an
apoptosis inhibitor, (c) transforming or transfecting the host
cell(s) with the vector referred to in step (a), (d) providing cell
culture media, (e) culturing the transformed or transfected host
cell(s) in the culture media under conditions sufficient to express
the protein of interest and the apoptosis inhibitor, and (f)
freezing and subsequently thawing the host cells and/or cell
culture media. Optionally, the gene encoding the apoptosis
inhibitor may be stably integrated into the genome of the host
cell. Optionally, the method includes the further step of admixing
an additional apoptosis inhibitor molecule into the culture media.
Optionally, the method provides for transient expression of the
protein of interest and stable or transient expression of the
apoptosis inhibitor.
[0017] In another embodiment, the method includes the steps of (a)
providing a vector comprising a gene encoding a protein of
interest, (b) providing a host cell, (c) transforming or
transfecting the host cell with the vector referred to in step (a),
(d) providing cell culture media, (e) providing an apoptosis
inhibitor, (f) admixing the apoptosis inhibitor into the culture
media, (g) culturing the host cell(s) in the culture media under
conditions sufficient to express the protein of interest, and (h)
freezing and subsequently thawing the host cells and/or the cell
culture media. Optionally, the method provides for transient
expression of the protein of interest.
[0018] In a still further embodiment, the invention provides for
improved transfection methods wherein use of one or more apoptosis
inhibitor(s) and increased concentrations of transfection reagent
can be employed to increase transfection efficiency.
[0019] In an even further embodiment, the invention provides a
protein of interest produced in accordance with any of the methods
described herein. The protein of interest may comprise a mammalian
protein or non-mammalian protein, and may optionally comprise a
receptor or a ligand. In one embodiment of the invention, the
protein of interest will comprise a protein which itself is capable
of inducing apoptosis in mammalian or non-mammalian cells in vitro
or in vivo, such as Apo-2 ligand/TRAIL, Fas ligand, or
TNF-alpha.
BRIEF DESCRIPTION OF THE DRAWINGS
[0020] FIG. 1A shows a graph illustrating cell viability of CHO
cells grown in a 2 liter bioreactor. The data show that the cells
grown in bioreactors may begin to lose viability as early as day 3,
often followed by a dramatic drop in viability on the following
day(s).
[0021] FIG. 1B shows a graph illustrating the results of three
apoptosis assays performed on the CHO cells. (referred to in FIG.
1A and Example 1): caspase-3 activation, DNA fragmentation and
annexin/PI binding (plasma membrane ("PM") changes). Activation of
caspases was first detected on day 3, the day that drop in
viability was detected (FIG. 1A).
[0022] FIG. 2 shows a Western blot analysis of lysates from
caspase-9-DN transfected clones. A clone transfected with a mpsv
vector (alone) was used as a control. The blot was probed with
rabbit anti-caspase-9 antiserum (Pharmingen) and developed using
chemiluminescence.
[0023] FIG. 3 shows the results of an assay wherein caspase-9-DN
clones 2 and 14, as well as controls (E25 untransfected cells and
mpsv vector transfected cells) were incubated with an apoptosis
inducer, staurosporine (1 micromolar). Samples were taken and cells
were analyzed for the % of viable cells.
[0024] FIG. 4 shows an analysis of caspase-3 activity for cell
samples taken at 24 hours post-induction with 1 micromolar
staurosporine.
[0025] FIGS. 5-8 show assay results of caspase-9-DN expressing
clones 2 and 14, as well as controls, scaled up and seeded at 1
million cells/ml in a 2 liter bioreactor. Samples were taken daily
and were analyzed for viability (FIG. 5), viable cell count (FIG.
6), activity of caspase-3 (FIG. 7) and the concentration of the
protein of interest (E25 antibody) secreted into the medium (FIG.
8).
[0026] FIGS. 9-10 show assay results of CHO cells seeded in 60 mm
dishes and exposed to caspase inhibitor, z-VAD-fmk (added to the
cell culture at 100 micromolar concentration, 48 hours after
seeding). The z-VAD-fmk inhibitor was added to the culture every 24
hours thereafter. Samples were taken every day and analyzed for
caspase-3 activity (FIG. 9) and the % viable cells (FIG. 10).
[0027] FIGS. 11-12 show assay results of a Baculovirus p35
expressing clone grown in a 2 liter bioreactor and assayed daily
for cell viability (FIG. 11) and caspase-3 activity (FIG. 12). The
control is a clone transfected with a vector, cpc.
[0028] FIG. 13 shows a bar diagram of the effects of various
concentrations of the transfection reagent, DMRIE-C, on cell
viability.
[0029] FIG. 14 shows a comparison of total and viable transfection
efficiencies obtained for caspase-9-DN clone 14 and controls; CHO
DP12 cells and E25 antibody expressing CHO DP12 cells.
[0030] FIG. 15 shows a comparison of the specific productivity (as
measured in Dnase titer/total LDH) obtained for caspase-9-DN clone
14 and controls, CHO DP12 cells and E25 antibody expressing CHO
DP12 cells.
[0031] FIG. 16 shows a comparison of the DNase titer obtained for
caspase-9-DN clone 14 and controls, CHO DP12 cells and E25 antibody
expressing CHO DP12 cells.
[0032] FIGS. 17 and 18 show viability and titers of caspase-9-DN
and E25 control grown in 2 liter bioreactors with temperature
shift, concentrated medium and a feed.
[0033] FIGS. 19 and 20 show viability and viable cell count of
cultures of E25 control and caspase-9-DN clone 14 seeded into
spinners from frozen vials. Data were obtained by trypan blue
exclusion.
[0034] FIGS. 21 and 22 show viability and E25 titers of cultures of
E25 control cells and caspase-9-DN clone 14 upon induction of
expression by butyrate.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] I. Definitions
[0036] The term "apoptosis inhibitor" is used herein to refer to a
molecule or substance whose expression or presence in an in vitro
cell culture provides a reduction or inhibition of apoptosis in the
cultured cells, or provides resistance of the cultured cells to
apoptotic stimuli. The apoptosis inhibitor may comprise a protein
or protein-like molecule, or an organic or inorganic molecule. The
apoptosis inhibitor may be present (and/or function)
intracellularly, extracellularly, or at the cell surface (membrane)
of the cultured cells. Particular apoptosis inhibitors contemplated
by the present invention include, but are not limited to, the
caspase-9 dominant negative (caspase-9-DN) mutant, bcl-2,
baculovirus p35, caspase-9S (Seol,D. W. et al., J. Biol. Chem.,
274, 2072-2076 (1999)), crmA, z-VAD-fmk, z-DEVD-fmk, B-D-fmk, and
z-YVAD-fmk, and variants therof. Preferably, the apoptosis
inhibitor is one which acts upon one or more caspases located
downstream in the intracellular cell death pathway of the cell,
such as caspase-3. Optionally, the apoptosis inhibitor will, in an
effective amount, decrease or reduce apoptosis in a cell culture by
at least 50% , preferably, by at least 75%, more preferably, by at
least 85%, and even more preferably, by at least 95% , as compared
to a control cell culture which contains no such apoptosis
inhibitor. Apoptosis or apoptotic activity in such cell cultures
can be measured and determined using assays such as described
herein. Optionally, the apoptosis inhibitor, in an effective
amount, will enhance or increase yield of the recombinant protein
of interest by at least 1-fold, and preferably by at least 2-fold,
as compared to a control cell culture which contains no such
apoptosis inhibitor. Optionally, the apoptosis inhibitor, in an
effective amount, will enhance or increase transfection efficiency
in transient transfections, preferably by at least 1-fold and more
preferably, by at least 2-fold, as compared to a control cell
culture which contains no such apoptosis inhibitor.
[0037] The term "protein of interest" refers to any protein which
may be useful for research, diagnostic or therapeutic purposes. The
protein of interest may comprise a mammalian protein or
non-mammalian protein, and may optionally comprise a receptor or a
ligand. Exemplary proteins of interest include, but are not limited
to, molecules such as renin; a growth hormone, including human
growth hormone and bovine growth hormone; growth hormone releasing
factor; parathyroid hormone; thyroid stimulating hormone;
lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin
B-chain; proinsulin; follicle stimulating hormone; calcitonin;
luteinizing hormone; glucagon; clotting factors such as factor
VIIIC, factor IX, tissue factor, and von Willebrands factor;
anti-clotting factors such as Protein C; atrial natriuretic factor;
lung surfactant; a plasminogen activator, such as urokinase or
human urine or tissue-type plasminogen activator (t-PA); bombesin;
thrombin; hemopoietic growth factor; members of the TNF and TNF
receptor (TNFR) family, like tumor necrosis factor-alpha and -beta,
CD40 ligand, Apo-2 ligand/TRAIL, DR4, DR5, DcR1, DcR2, DcR3, OPG,
Fas ligand; enkephalinase; RANTES (regulated on activation normally
T-cell expressed and secreted); human macrophage inflammatory
protein (MIP-1-alpha); a serum albumin such as human serum albumin;
Muellerian-inhibiting substance; relaxin A-chain; relaxin B-chain;
prorelaxin; mouse gonadotropin-associated peptide; a microbial
protein, such as beta-lactamase; DNase; IgE; a cytotoxic
T-lymphocyte associated antigen (CTLA), such as CTLA-4; inhibin;
activin; vascular endothelial growth factor (VEGF),; receptors for
hormones or growth factors; protein A or D; rheumatoid factors; a
neurotrophic factor such as bone-derived neurotrophic factor
(BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6),
or a nerve growth factor such as NGF-.beta.; platelet-derived
growth factor (PDGF); fibroblast growth factor such as aFGF and
bFGF; epidermal growth factor (EGF); transforming growth factor
(TGF) such as TGF-alpha and TGF-beta, including TGF-.beta.1,
TGF-.beta.2, TGF-.beta.3, TGF-.beta.4, or TGF-.beta.5; insulin-like
growth factor-I and -II (IGF-I and IGF-II); des (1-3)-IGF-I (brain
IGF-I), insulin-like growth factor binding proteins; CD proteins
such as CD3, CD4, CD8, CD19 and CD20; erythropoietin;
osteoinductive factors; immunotoxins; a bone morphogenetic protein
(BMP); an interferon such as interferon-alpha, -beta, and -gamma;
colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF;
thrombopoietin (TPO); interleukins (ILs), e.g., IL-1 to IL-10;
superoxide dismutase; T-cell receptors; surface membrane proteins;
decay accelerating factor; viral antigen such as, for example, a
portion of the AIDS envelope, gp120; transport proteins; homing
receptors; addressins; regulatory proteins; integrins such as
CD11a, CD11b, CD11c, CD18, an ICAM, VLA-4 and VCAM; a tumor
associated antigen such as HER2, HER3 or HER4 receptor; and
variants and/or fragments of any of the above-listed polypeptides;
as well as antibodies against various protein antigens like CD
proteins such as CD3, CD4, CD8, CD19, CD20 and CD34; members of the
ErbB receptor family such as the EGF receptor, HER2, HER3 or HER4
receptor; cell adhesion molecules such as LFA-1, Mac1, p150.95,
VLA-4, ICAM-1, VCAM and .alpha.v/.beta.3 integrin including either
.alpha. or .beta. subunits thereof (e.g. anti-CD11a, anti-CD18 or
anti-CD11b antibodies); growth factors such as VEGF; IgE; blood
group antigens; flk2/flt3 receptor; obesity (OB) receptor; mpl
receptor; CTLA-4; protein C; an Apo-2L receptor such as Apo-2
(DR5), DR4, DcR1, DcR2, DcR3; and variants and/or fragments of the
above-identified antibodies etc. In one embodiment of the
invention, a protein of interest will comprise a protein which
itself is capable of inducing apoptosis in mammalian or
non-mammalian cells in vitro or in vivo, such as Apo-2
ligand/TRAIL, Fas ligand, or-TNF-alpha.
[0038] "Isolated," when used to describe the various proteins of
interest disclosed herein, means protein that has been identified
and separated and/or recovered from a component of its natural
environment. Contaminant components of its natural environment are
materials that would typically interfere with research, diagnostic
or therapeutic uses for the protein of interest, and may include
enzymes, hormones, and other proteinaceous or non-proteinaceous
solutes. In preferred embodiments, the protein will be purified (1)
to a degree sufficient to obtain at least 15 residues of N-terminal
or internal amino acid-sequence by use of a spinning cup
sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or
reducing conditions using Coomassie blue or, preferably, silver
stain. Isolated protein includes protein in situ within recombinant
cells, since at least one component of the protein of interest's
natural environment will not be present. Ordinarily, however,
isolated protein will be prepared by at least one purification
step.
[0039] The term "control sequences" refers to DNA sequences
necessary for the expression of an operably linked coding sequence
in a particular host organism. The control sequences that are
suitable for prokaryotes, for example, include a promoter,
optionally an operator sequence, and a ribosome binding site.
Eukaryotic cells are known to utilize promoters, polyadenylation
signals, and enhancers.
[0040] Nucleic acid is "operably linked" when it is placed into a
functional relationship with another nucleic acid sequence. For
example, DNA for a presequence or secretory leader is operably
linked to DNA for a polypeptide if it is expressed as a preprotein
that participates in the secretion of the polypeptide; a promoter
or enhancer is operably linked to a coding sequence if it affects
the transcription of the sequence; or a ribosome binding site is
operably linked to a coding sequence if it is positioned so as to
facilitate translation. Generally, "operably linked" means that the
DNA sequences being linked are contiguous, and, in the case of a
secretory leader, contiguous and in reading phase. However,
enhancers do not have to be contiguous. Linking is accomplished by
ligation at convenient restriction sites. If such sites do not
exist, the synthetic oligonucleotide adaptors or linkers are used
in accordance with conventional practice.
[0041] As used herein, the expressions "cell", "cell line", and
"cell culture" are used interchangeably and all such designations
include progeny. Thus, the terms "transformants" and
"transfectants" include the primary subject cell and cultures
derived therefrom without regard for the number of transfers.
[0042] "Growth phase" of the cell culture refers to the period of
exponential cell growth (the log phase) where cells are generally
rapidly dividing. During this phase, cells are cultured for a
period of time, usually between 1-4 days, and under such conditions
that cell growth is maximized. The determination of the growth
cycle for the host cell can be determined for the particular host
cell envisioned without undue experimentation. "Period of time and
under such conditions that cell growth is maximized" and the like,
refer to those culture conditions that, for a particular cell line,
are determined to be optimal for cell growth and division. During
the growth phase, cells are cultured in nutrient medium containing
the necessary additives generally at about 30-40.degree. C.,
preferably about 37.degree. C., in a humidified, controlled
atmosphere, such that optimal growth is achieved for the particular
cell line. Cells are maintained in the growth phase for a period of
about between one and four days, usually between two to three
days.
[0043] "Transition phase" of the cell culture refers to the period
of time during which culture conditions for the production phase
are engaged. During the transition phase environmental factors such
as pH, ion concentration, and temperature may shifted from growth
conditions to production conditions.
[0044] "Production phase, of the cell culture refers to the period
of time during which cell growth has reached a plateau. During the
production phase, logarithmic cell growth has ended and protein
production is primary. During this period of time the medium is
generally supplemented to support continued protein production and
to achieve the desired protein product.
[0045] The term "expression" or "expresses" is used herein to refer
to transcription and translation occurring within a host cell. The
level of expression of a product gene in a host cell may be
determined on the basis of either the amount of corresponding mRNA
that is present in the cell or the amount of the protein encoded by
the product gene that is produced by the cell. For example, mRNA
transcribed from a product gene is desirably quantitated by
northern hybridization. See, e.g., Sambrook et al., Molecular
Cloning: A Laboratory Manual, pp. 7.3-7.57 (Cold Spring Harbor
Laboratory Press, 1989). Protein encoded by a product gene can be
quantitated either by assaying for the biological activity of the
protein or by employing assays that are independent of such
activity, such as western blotting or radioimmunoassay using
antibodies that are capable of reacting with the protein. See,
e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, pp.
18.1-18.88 (Cold Spring Harbor Laboratory Press, 1989).
[0046] The terms "apoptosis" and "apoptotic activity" are used in a
broad sense and refer to the orderly or controlled form of cell
death in mammalian or non-mammalian cells that is typically
accompanied by one or more characteristic cell changes, including
condensation of cytoplasm, loss of plasma membrane microvilli,
activation of caspase(s), segmentation of the nucleus, degradation
of chromosomal DNA or loss of mitochondrial function. This activity
can be determined and measured, for instance, by cell viability
assays, FACS analysis, annexin V binding, or DNA electrophoresis
such as is known in the art and described further herein.
[0047] II. The Methods of the Invention
[0048] Cells grown in cell culture may begin to lose viability
within days of initiating the culture. Loss of cell viability can
particularly be problematic when culturing cells in relatively
large, batch scale cultures or bioreactors. For instance, CHO cells
grown in batch culture can begin to lose cell viability as early as
Day 4 after which a rapid decline in viability can continue until
the culture is terminated. The mechanism by which such cultured
cells die may be either through necrosis or apoptosis. Using TUNEL
and Annexin/PI binding assays, Applicants discovered that
approximately 80% of some CHO cells grown in batch culture may die
by apoptosis rather than through necrosis. As described herein,
Applicants have surprisingly found methods which allow a marked
reduction of such apoptosis.
[0049] The methods disclosed in the present application have a
variety of applications and improvements for recombinant protein
production. First, by prolonging host cell viability in culture
(and during fermentation), one skilled in the art can increase
production and yield of the protein of interest. This can improve
the efficiency of the cell culture run and result in marked cost
savings. Further, Applicants have found the use of one or more
apoptosis inhibitors in the methods of the invention may protect
against potential adverse effects of agents like butyrate or TSA
included in the cell culture. Also, the methods herein can enhance
quality of the expressed and recovered protein of interest. The
quality of the expressed and recovered protein of interest may be
evaluated using techniques known in the art, such as SDS-PAGE, etc.
The occurrence of cell death in recombinant cell cultures
oftentimes results in the release of various active proteins from
the dying cells, such as proteases [Lao, M., et al.,
Cytotechnology, 22: 43-52 (1996); Teige, M., et al., J.
Biotechnol., 34:101-105 (1994)], glycosidases such as sialidase or
.beta.-galactosidase [Gramer M. J. and Goochee C. F., Biotechnol.
Prog., 9:366-373 (1999)], or proline isomerase [Schmid, Current
Biology, 5:933-944 (1995)]. These and other such proteins are often
capable of degrading the product quality or function of the desired
recombinant protein(s) being expressed, for instance, by undesired
cleavage, carbohydrate modification (glycoprotein
modification)[Wittwer A., and Howard, S. C., Biochem., 29:4175-4180
(1990); Hart, Curr. OP. Cell Biol., 4:1017-1023 (1992); Goochee, et
al., Bio/Technology, 9:1347-1355 (1991)], or protein structure
modification (such as folding or aggregation). By decreasing or
inhibiting apoptosis in the cell culture, the present methods can
decrease the number or presence of such adverse proteases in the
culture media and protect the expressed protein of interest against
proteolytic degradation.
[0050] The methods herein can further be employed to increase
transfection efficiency and viability of cells during transfection.
Reagents used in various transfection techniques, such as
Lipofectamine or DMRIE-C (Gibco), can be relatively toxic to the
cells when used in higher concentrations. The use of higher
concentrations of transfection reagents, however, would be
particularly helpful to achieve higher transfection efficiencies.
The expression of apoptosis inhibitor and/or the addition of
apoptosis inhibitor directly to the cell culture medium can be used
to reduce or inhibit cell death even when such higher
concentrations of a transfection reagent are selected. The use of
apoptosis inhibitor in this manner can result in higher
transfection efficiency and higher yield of the recombinant protein
of interest.
[0051] The methods disclosed can be further used to express
proteins of interest which are proteins that, themselves, induce
apoptosis. Such proteins like Apo-2 ligand/TRAIL or Fas ligand, can
trigger apoptosis when expressed in cells. The presence of
apoptosis inhibitor(s), in accordance with the present methods, may
block such apoptotic activity and allow for improved expression of
the protein of interest.
[0052] In addition, the methods can be used to increase the
viability of cells undergoing freezing/storage/thawing procedures.
During these procedures generally, cells can lose viability. The
presence of apoptosis inhibitor(s) expressed in cells (or added to
the cell culture media) can provide for increased cell viability
and aid in reducing or eliminating the variability in cell
viabilities between aliquots or vials of cells.
[0053] The methods according to the present invention are described
in further detail below.
[0054] The DNA encoding the protein of interest may be obtained
from a variety of sources, for instance, from any cDNA library
prepared from tissue believed to possess its mRNA and to express it
at a detectable level. The gene encoding the protein of interest
may also be obtained from a genomic library or by oligonucleotide
synthesis. Screening such a cDNA or genomic library with a selected
probe may be conducted using standard procedures, such as described
in Sambrook et al., Molecular Cloning: A Laboratory Manual (New
York: Cold Spring Harbor Laboratory Press, 1989). An alternative
means to isolate the gene encoding the protein of interest is to
use PCR methodology [Sambrook et al., supra; Dieffenbach et al.,
PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory
Press, 1995)].
[0055] Various proteins of interest have been specifically referred
to above and their respective gene sequences are generally known
and publicly available.
[0056] Genes encoding various apoptosis inhibitors have also been
described in the literature [see e.g., Clem R. J. et al., Science,
254, 1388-1390 (1991); Duan, H. et al., J. Biol. Chemistry, 271,
16720-16724 (1996); Pan, G. et al., J. Biol. Chemistry, 273,
5841-5845 (1998); Vaux, D. L. et al., Science, 258, 1955-1957
(1998); Tsujimoto et al., Proc. Natl. Acad. Sci., 83:5214-5218
(1986)]. The methods of the present invention contemplate the use
of a single apoptosis inhibitor-encoding gene as well as the use of
a combination of two or more apoptosis inhibitor-encoding genes.
Potentially, the expression of two or more types of apoptosis
inhibitor(s) in a host cell may be beneficial in controlling
apoptosis in the cell culture. One skilled in the art can monitor
the quantity or amount of apoptosis inhibitor being expressed by
the host cells, such as by a Western blot analysis using an
antibody that recognizes the apoptosis inhibitor. The quantity or
amount of apoptosis inhibitor, as well as the timing of its
expression, can be regulated or monitored, for instance, by
choosing a vector with an inducible promoter.
[0057] When selecting an apoptosis inhibitor for use in the claimed
methods, those skilled in the art will appreciate that various
apoptosis inhibitor molecules may act upon different intracellular
components of the signaling pathway which leads to cell death. The
pathways involved in cell death comprise a family of cysteine
proteases, called caspases, that are related to the mammalian
interleukin-1beta converting enzyme (caspase-1) and to Ced3, the
product of a gene of C. elegans. It is believed that such caspase
molecules can act at at least two different levels. Initiator
caspases are typically "upstream" molecules that are activated in
response to stimuli indicating that the cell has been stressed,
damaged, or received some form of signal to initiate cell death by
apoptosis. An example of such an upstream caspase is caspase-8.
Initiator caspases can then, in turn, cleave and activate another
family of "downstream" caspases, such as caspase-3. Depending upon
the nature of the apoptotic stimulus as well as the cell type, only
a portion of the signaling pathway may be involved in the signaling
mechanism and execution of cell death. For example, certain
apoptosis inhibitors, such as CrmA, are believed to act upon
caspases, such as caspase-8, located upstream and are usually
directly activated by death receptor binding to ligand. Other
apoptosis inhibitors are believed to act upon other caspases
located downstream in the intracellular signaling pathway. Thus, it
is is presently believed that inhibitors of those molecule(s) that
are effectively engaged (such as actively engaged in the signal
transmission) in the cell death apparatus in a selected cell will
be effective as apoptosis inhibitors, as described herein.
Applicants do note, however, that those skilled in the art will
understand that in such signaling pathways, there is point at which
the cell is "committed" to cell death, and once the signaling
pathway has transmitted a signal(s) to the point where the cell is
committed to cell death, apoptosis inhibitor molecules, like those
described herein, may not be effective in inhibiting or preventing
the apoptosis of the "committed" cell.
[0058] The cytokine response modifier, CrmA, is a 38 kDa serpin
identified from cowpox virus that has been reported to inhibit
apoptosis in several systems [Gagliardini et al., Science,
263:826-828 (1994); Tewari et al., J. Biol. Chem., 270:3255-3260
(1995)]. CrmA has been evaluated as an inhibitor of caspase-1 and
caspase-8 [Nicholson et al., Nature, 376:37-43 (1995); Zhou et al.,
J. Biol. Chem., 272:7797-7800 (1997)]. In some studies conducted by
Applicants, it was observed that overexpression of CrmA in CHO
dhfr+ cells was unable to substantially delay cell death in the
environment of a bioreactor. This result suggested that in this
particular CHO cell system selected by Applicants, neither
caspase-1 nor caspase-8 were actively involved in the cell death
pathway of those particular cultured cells. Accordingly, to achieve
the desired effects described herein, it is preferred to select an
apoptosis inhibitor molecule which acts downstream in the selected
host cell's cell death signaling pathway, but prior to the point
where the cell has been committed to cell death.
[0059] The nucleic acids (e.g., cDNA or genomic DNA) encoding the
protein of interest and the apoptosis inhibitor may be inserted
into replicable vector(s) for expression. Various vectors are
publicly available. The vector components generally include, but
are not limited to, one or more of the following: a signal
sequence, an origin of replication, one or more marker genes, an
enhancer element, a promoter, and a transcription termination
sequence, each of which is described below. Optional signal
sequences, origins of replication, marker genes, enhancer elements
and transcription terminator sequences that may be employed are
known in the art and described in further detail in WO97/25428.
[0060] Techniques for inserting such genes into vectors are well
known to the skilled artisan and such techniques can be
accomplished without undue experimentation. Construction of
suitable vectors can employ standard ligation techniques. Isolated
plasmids or DNA fragments are cleaved, tailored, and re-ligated in
the form desired to generate the plasmids required. Techniques
known in the art may be employed. [See, e.g., Messing et al.,
Nucleic Acids Res., 9:309 (1981); Maxam et al., Methods in
Enzymology, 65:499 (1980)].
[0061] The gene encoding the apoptosis inhibitor and the gene
encoding the protein of interest may be inserted into a single
vector (co-transfected), or be inserted into two separate or
different vectors. Preferably, the respective genes are inserted
into two separate vectors. Each such vector will typically contain
a selection gene, also termed a selectable marker. Typical
selection genes encode proteins that (a) confer resistance to
antibiotics or other toxins, e.g., ampicillin, neomycin, puromycin,
methotrexate, or tetracycline, (b) complement auxotrophic
deficiencies, or (c) supply critical nutrients not available from
complex media, e.g., the gene encoding D-alanine racemase for
Bacilli.
[0062] An example of suitable selectable markers for mammalian
cells are those that enable the identification of cells competent
to take up the encoding nucleic acid, such as DHFR or thymidine
kinase. An appropriate host cell when wild-type DHFR is employed is
the CHO cell line deficient in DHFR activity, prepared and
propagated as described by Urlaub et al., Proc. Natl. Acad. Sci.
USA, 77:4216 (1980). A suitable selection gene for use in yeast is
the trp1 gene present in the yeast plasmid YRp7 [Stinchcomb et al
., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979);
Tschemper et al., Gene, 10:157 (1980)]. The trp1 gene provides a
selection marker for a mutant strain of yeast lacking the ability
to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1
[Jones, Genetics, 85:12 (1977)].
[0063] In the methods employing a first vector comprising an
apoptosis inhibitor gene and a second vector comprising a gene
encoding the protein of interest, it is preferred that the first
and second vector carry different selection markers. For example, a
vector comprising the apoptosis inhibitor gene might carry a
selection gene to confer ampicillin resistance while the vector
comprising the gene encoding the protein of interest might carry a
selection gene to confer methotrexate resistance.
[0064] Expression vectors usually also contain a promoter that is
recognized by the host organism and is operably linked to the
inserted nucleic acid sequence(s) described above. Promoters are
untranslated sequences located upstream (5') to the start codon of
a structural gene (generally within about 100 to 1000 bp) that
control the transcription and translation of a particular nucleic
acid sequence, to which they are operably linked. Such promoters
typically fall into two classes, inducible and constitutive.
Inducible promoters are promoters that initiate increased levels of
transcription from DNA under their control in response to some
change in culture conditions, e.g., the presence or absence of a
nutrient or a change in temperature. At this time a large number of
promoters recognized by a variety of potential host cells are well
known. These promoters are operably linked to the encoding DNA by
removing the promoter from the source DNA by restriction enzyme
digestion and inserting the isolated promoter sequence into the
vector.
[0065] Promoters suitable for use with prokaryotic and eukaryotic
hosts are known in the art, and are described in further detail in
WO97/25428.
[0066] Expression vectors that provide for the transient expression
of DNA encoding the protein of interest may be employed. In
general, transient expression involves the use of an expression
vector that is able to replicate efficiently in a host cell, such
that the host cell accumulates many copies of the expression vector
and, in turn, synthesizes high levels of a desired protein encoded
by the expression vector [Sambrook et al., supra]. Transient
expression systems, comprising a suitable expression vector and a
host cell, allow for the convenient positive identification of
proteins encoded by cloned DNAs, as well as for the rapid screening
of such proteins for desired biological or physiological
properties.
[0067] Host cells are transfected or transformed with the
above-described expression vectors for production of the protein of
interest and cultured in nutrient media modified as appropriate for
inducing promoters, selecting transformants, or amplifying the
genes encoding the desired sequences.
[0068] Transfection refers to the taking up of an expression vector
by a host cell whether or not any coding sequences are in fact
expressed. Numerous methods of transfection are known to the
ordinarily skilled artisan, for example, CaPO.sub.4 and
electroporation. Successful transfection is generally recognized
when any indication of the operation of this vector occurs within
the host cell. As described above, the use of an apoptosis
inhibitor gene (or adding an apoptosis inhibitor molecule directly
to the culture media) may improve transfection efficiency. It is
believed that use of such apoptosis inhibitor(s) will allow for use
of increased amounts of transfection reagents, such as
Lipofectamine or DMRIE-C (as described in the Examples below).
[0069] Transformation means introducing DNA into an organism so
that the DNA is replicable, either as an extrachromosomal element
or by chromosomal integrant. Depending on the host cell used,
transformation is done using standard techniques appropriate to
such cells. The calcium treatment employing calcium chloride, as
described in Sambrook et al., supra, or electroporation is
generally used for prokaryotes or other cells that contain
substantial cell-wall barriers. Infection with Agrobacterium
tumefaciens is used for transformation of certain plant cells, as
described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859
published Jun. 29, 1989. In addition, plants may be transfected
using ultrasound treatment as described in WO 91/00358 published
Jan. 10, 1991. For mammalian cells without such cell walls, the
calcium phosphate precipitation method of Graham and van der Eb,
Virology, 52:456-457 (1978) can be employed. General aspects of
mammalian cell host system transformations have been described in
U.S. Pat. No. 4,399,216. Transformations into yeast are typically
carried out according to the method of Van Solingen et al., J.
Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci.
(USA), 76:3829 (1979). However, other methods for introducing DNA
into cells, such as by nuclear microinjection, electroporation,
bacterial protoplast fusion with intact cells, or polycations,
e.g., polybrene, polyornithine, may also be used. For various
techniques for transforming mammalian cells, see Keown et al.,
Methods in Enzymology, 185:527-537 (1990) and Mansour et al.,
Nature, 336:348-352 (1988).
[0070] Suitable host cells for expressing the DNA in the vectors
herein include prokaryote, yeast, or higher eukaryote cells.
Suitable prokaryotes include but are not limited to eubacteria,
such as Gram-negative or Gram-positive organisms, for example,
Enterobacteriaceae such as E. coli. Various E. coli strains are
publicly available, such as E. coli K12 strain MM294 (ATCC 31,446);
E. coli X1776 (ATCC 31,537); E. coli strain W3110 (ATCC 27,325) and
K5 772 (ATCC 53,635); Enterobacter, Erwinia, Klebsiella, Proteus,
Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia
marcescans, and Shigella, as well as Bacilli such as B. subtilis
and B. licheniformis (e.g., B. licheniformis 41P disclosed in DD
266,710 published Apr. 12, 1989), Pseudomonas such as P.
aeruginosa, and Streptomyces.
[0071] In addition to prokaryotes, eukaryotic microbes such as
filamentous fungi or yeast are suitable. Saccharomyces cerevisiae
is a commonly used lower eukaryotic host microorganism.
[0072] Suitable host cells may be derived from multicellular
organisms. Examples of invertebrate cells include insect cells such
as Drosophila S2 and Spodoptera Sf9, as well as plant cells.
Examples of useful mammalian host cell lines include Chinese
hamster ovary (CHO) and COS cells. More specific examples include
monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651);
human embryonic kidney line (293 or 293 cells subcloned for growth
in suspension culture, Graham et al., J. Gen Virol., 36:59 (1977));
Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc.
Natl. Acad. Sci. USA, 77:4216 (1980)); dp12.CHO (EP 307, 247
published Mar. 15, 1989), mouse sertoli cells (TM4, Mather, Biol.
Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75);
human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT
060562, ATCC CCL51). The selection of the appropriate host cell is
deemed to be within the skill in the art.
[0073] The selection of a particular apoptosis inhibitor to employ
with a particular host cell and protein of interest can be made
without undue experimentation by one of ordinary skill in the
art.
[0074] Prokaryotic cells used to produce the protein of interest
may be cultured in suitable culture media as described generally in
Sambrook et al., supra. Particular forms of culture media that may
be employed for culturing CHO are described further in the Examples
below. Mammalian host cells used to produce the protein of interest
may be cultured in a variety of culture media. Suitable culture
conditions for mammalian cells are well known in the art (J.
Immunol. Methods (1983) 56:221-234) or can be easily determined by
the skilled artisan (see, for example, Animal Cell Culture: A
Practical Approach 2nd Ed., Rickwood, D. and Hames, B. D., eds.
Oxford University Press, New York (1992)), and vary according to
the particular host cell selected.
[0075] Examples of commercially available culture media include
Ham's F10 (Sigma), Minimal Essential Medium ("MEM", Sigma),
RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ("DMEM",
Sigma). In addition, any of the media described in Ham and Wallace,
(1979) Meth. Enz., 58:44; Barnes and Sato, (1980) Anal. Biochem.,
102:255; U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 5,122,469
or 4,560,655; International Publication Nos. WO 90/03430; and WO
87/00195 may be used. Any such media may be supplemented as
necessary with hormones and/or other growth factors (such as
insulin, transferrin, or epidermal growth factor), salts (such as
sodium chloride, calcium,.magnesium, and phosphate), buffers (such
as HEPES), nucleosides (such as adenosine and thymidine),
antibiotics (such as Gentamycin.TM. drug), trace elements (defined
as inorganic compounds usually present at final concentrations in
the micromolar range), and glucose or an equivalent energy source.
Any other necessary supplements may also be included at appropriate
concentrations that would be known to those skilled in the art. The
culture conditions, such as temperature, pH, and the like, are
those previously used with the host cell selected for expression,
and will be apparent to the ordinarily skilled artisan. The
necessary growth factors for a particular cell are readily
determined empirically without undue experimentation, as described
for example in Mammalian Cell Culture (Mather, J. P. ed., Plenum
Press, N.Y. (1984), and Barnes and Sato, (1980) Cell, 22:649.
[0076] Other methods, vectors, and host cells suitable for
adaptation to the synthesis of the protein of interest in
recombinant vertebrate cell culture are described in Gething et
al., Nature 293:620-625 (1981); Mantei et al., Nature, 281:40-46
(1979); EP 117, 060; and EP 117, 058. In general, principles,
protocols, and practical techniques for maximizing the productivity
of mammalian cell cultures can be found in Mammalian Cell
Biotechnology: A Practical Approach, M. Butler, ed. (IRL Press,
1991).
[0077] The amount of apoptosis inhibitor added directly, or
admixed, to the culture media will depend on various factors, for
instance, the type of apoptosis inhibitor molecule being employed,
the type of host cell, culture conditions, etc. Determining the
desired concentration of apoptosis inhibitor to be added to the
culture media is within the skill in the art and can be ascertained
empirically without undue experimentation. Preferably, an effective
amount or desired concentration of apoptosis inhibitor added
directly to the culture media is such that the apoptosis inhibitor
penetrates into the host cell. The skilled artisan will readily
appreciate that different apoptosis inhibitors may have different
abilities to penetrate into the host cell, and therefore, one
should choose a concentration which allows for such penetration
into the host cell. There will typically be an upper range of
concentration of apoptosis inhibitor which may not be desirable as
the concentration approaches a range which is adverse or toxic to
the host cells. As described in the Examples below, Applicants have
found that z-VAD-fmk can inhibit apoptosis when added to cell
cultures at a concentration of about 100 micromolar. A variety of
apoptosis inhibitor compounds such as z-VAD-fmk, z-DEVD-fmk,
B-D-fmk, and z-YVAD-fmk are available from vendors, such as
Pharmingen and Enzyme Systems, Livermore, CA.
[0078] The apoptosis inhibitor may be added directly into the
culture media. The apoptosis inhibitor may be added at any point
during the culturing of the cells. Optionally, the apoptosis
inhibitor is added to the culture media at the beginning (at. the
time of initiating, day 0) of the cell. culturing process.
Preferably, such an apoptosis inhibitor would be added to the
culture media during the culturing of the cells but prior to the
point when induction of apoptosis occurs; typically, induction of
apoptosis can be observed in large scale cell cultures on about day
3 or day 4 of the culture, and therefore, the apoptosis inhibitor
will preferably be added prior to day 3 or day 4. Optionally, a
desired quantity of apoptosis inhibitor is added throughout, or for
the duration of, the cell culture, for instance, on a daily basis
for the entire fermentation. As an example, for a 5 day culture,
the apoptosis inhibitor could be added at day 0, and every 24 hours
thereafter until the culture is terminated.
[0079] In one embodiment of the invention, the selected host cell
is a CHO cell, preferably, a dp12.CHO cell, and the selected
culture medium contains a basal medium component such as a DMEM/HAM
F-12 based formulation (for composition of DMEM and HAM F12 media
and especially serum free media, see culture media formulations in
American Type Culture Collection Catalogue of Cell Lines and
Hybridomas, Sixth Edition, 1988, pages 346-349) (the formulation of
medium as described in U.S. Pat. No. 5,122,469 are particularly
appropriate) with modified concentrations of some components such
as amino acids, salts, sugar, and vitamins, and optionally
containing glycine, hypoxanthine, and thymidine; recombinant human
insulin, hydrolyzed peptone, such as Primatone HS or Primatone RL
(Sheffield, England), or the equivalent; a cell protective agent,
such as Pluronic F68 or the equivalent pluronic polyol; Gentamycin;
and trace elements. Preferably, the selected cell culture media is
serum free.
[0080] The proteins of interest may be produced by growing the host
cells under a variety of cell culture conditions. For instance,
cell culture procedures for the large or small scale production of
proteins are potentially useful within the context of the present
invention. Procedures including, but not limited to, a fluidized
bed bioreactor, hollow fiber bioreactor, roller bottle culture, or
stirred tank bioreactor system may be used, in the later two
systems, with or without microcarriers, and operated alternatively
in a batch, fed-batch, or continuous mode.
[0081] In a preferred embodiment, the cell culture of the present
invention is performed in a stirred tank bioreactor system and a
fed batch culture procedure is employed. In the preferred
bioreactor system, the size of the bioreactors are sufficiently
large to produce the desired amount of protein of interest, such as
1,000 Liter or 12,000 Liter sizes, but are not limited to such
sizes as much smaller (i.e., 2 Liter, 400 Liter) or larger (i.e.,
25,000 Liter, 50,000 Liter) bioreactor vessels may be appropriate.
In the preferred fed batch culture, the mammalian host cells and
culture medium are supplied to a culturing vessel initially and
additional culture nutrients are fed, continuously or in discrete
increments, to the culture during culturing, with or without
periodic cell and/or product harvest before termination of culture.
The fed batch culture can include, for example, a semi-continuous
fed batch culture, wherein periodically whole culture (including
cells and medium) is removed and replaced by fresh medium. Fed
batch culture is distinguished from simple batch culture in which
all components for cell culturing (including the cells and all
culture nutrients) are supplied to the culturing vessel at the
start of the culturing process. Fed batch culture can be further
distinguished from perfusion culturing insofar as the supernate is
not removed from the culturing vessel during the process but at the
termination of the culture process (in perfusion culturing, the
cells are restrained in the culture by, e.g., filtration,
encapsulation, anchoring to microcarriers etc. and the culture
medium is continuously or intermittently introduced and removed
from the culturing vessel).
[0082] Further, the cultured cells may be propagated according to
any scheme or routine that may be suitable for the particular host
cell and the particular production plan contemplated. Therefore,
the present invention contemplates a single step or multiple step
culture procedure. In a single step culture, the host cells are
inoculated into a culture environment and the method steps of the
instant invention are employed during a single production phase of
the cell culture. Alternatively, a multi-stage culture is
envisioned. In the multi-stage culture, cells may be cultivated in
a number of steps or phases. For instance, cells may be grown in a
first step or growth phase culture wherein cells, possibly removed
from storage, are inoculated into a medium suitable for promoting
growth and high viability. The cells may be maintained in the
growth phase for a suitable period of time by the addition of fresh
medium to the host cell culture.
[0083] According to a preferred aspect of the invention, fed batch
or continuous cell culture conditions are devised to enhance growth
of the mammalian cells in the growth phase of the cell culture. In
the growth phase, cells are grown under conditions and for a period
of time that is maximized for growth. Culture conditions, such as
temperature, pH, dissolved oxygen (dO.sub.2) and the like, are
those used with the particular host and will be apparent to the
ordinarily skilled artisan. Generally, the pH is adjusted to a
level between about 6.5 and 7.5 using either an acid (e.g.,
CO.sub.2) or a base (e.g., Na.sub.2CO.sub.3 or NaOH). A suitable
temperature range for culturing mammalian cells such as CHO cells
is between about 30 to 38.degree. C. and preferably about
37.degree. C. and a suitable dO.sub.2 is between 5-90% of air
saturation.
[0084] At a particular stage the cells may be used to inoculate a
production phase or step of the cell culture. Alternatively, as
described above, the production phase or step may be continuous
with the inoculation or growth phase or step.
[0085] According to the present invention, the cell culture
environment during the production phase of the cell culture is
controlled. According to the steps of the presently disclosed
methods, the concentration of apoptosis inhibitor in the culture
medium can be manipulated such that the desired content and quality
of the protein of interest is achieved and maintained in the
resulting cell culture fluid. In a preferred aspect, the production
phase of the cell culture is preceded by a transition phase of the
cell culture in which expression of or addition of apoptosis
inhibitor(s) for the production phase of the cell culture are
engaged. Concentrations of apoptosis inhibitor(s) are preferably
monitored in connection with other process parameters such as the
osmolality of the production phase since osmolality can affect the
cell specific productivity.
[0086] In any of the above-described methods, it is contemplated
that it may be desirable to include a desired amount of agent like
butyrate or TSA in the cell culture medium. Various forms of
butyrate and its salts are known in the art, such as butyric acid
and sodium butyrate, and are publicly available from sources such
as Sigma Chemical Co. Butyrate has been reported in the literature
to enhance the productivity and protein expression of cell cultures
[Arts et al., Biochem J.., 310:171-176 (1995); Gorman et al.,
Nucleic Acids Res.., 11:7631-7648 (1983); Krugh, Mol. Cell.
Biochem., 42:65-82 (1982); Lamotte et al., Cytotechnology, 29:55-64
(1999); Chotigeat et al., Cytotechnology, 15:217-221 (1994)].
Trichostatin A (TSA) is an inhibitor of histone deacetylase and may
act similarly to butyrate in enhancing the productivity and protein
expression in cell cultures [Medina et al., Cancer Research,
57:3697-3707 (1997)]. Although butyrate has some positive effects
on protein expression, it is also appreciated in the art that at
certain concentrations, butyrate can induce apoptosis in the
cultured cells and-thereby decrease viability of the culture as
well as viable cell density [Hague et al., Int. J. Cancer,
55:498-505 (1993); Calabresse et al., Biochim. Biophys. Res. Comm.,
195:31-38 (1993); Fillipovich et al., Biochim. Biophys. Res. Comm.,
198:257-265 (1994); Medina et al., Cancer Research, 57:3697-3707
(1997)]. In the methods of the present invention, a desired amount
of butyrate or TSA may be added to the cell culture at the onset of
the production phase and more preferably, may be added to the cell
culture after a temperature shift has been implemented. Butyrate or
TSA can be added in a desired amount determined empirically by
those skilled in the art, but preferably, butyrate is added to the
cell culture at a concentration of about 1 to about 25 mM, and more
preferably, at a concentration of about 1 to about 6 mM.
[0087] Expression of the protein of interest may be measured in a
sample directly, for example, by ELISA, conventional Southern
blotting, Northern blotting to quantitate the transcription of mRNA
[Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot
blotting (DNA analysis), or in situ hybridization, using an
appropriately labeled probe. Various labels may be employed, most
commonly radioisotopes, and particularly .sup.32p. However, other
techniques may also be employed, such as using biotin-modified
nucleotides for introduction into a polynucleotide. The biotin then
serves as the site for binding to avidin or antibodies, which may
be labeled with a wide variety of labels, such as radionucleotides,
fluorescers or enzymes. Alternatively, antibodies may be employed
that can recognize specific duplexes, including DNA duplexes, RNA
duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The
antibodies in turn may be labeled and the assay may be carried out
where the duplex is bound to a surface, so that upon the formation
of duplex on the surface, the presence of antibody bound to the
duplex can be detected.
[0088] Gene expression, alternatively, may be measured by
immunological methods, such as immunohistochemical staining of
cells or tissue sections and assay of cell culture or body fluids,
to quantitate directly the expression of gene product. With
immunohistochemical staining techniques, a cell sample is prepared,
typically by dehydration and fixation, followed by reaction with
labeled antibodies specific for the gene product coupled, where the
labels are usually visually detectable, such as enzymatic labels,
fluorescent labels, luminescent labels, and the like.
[0089] Antibodies useful for immunohistochemical staining and/or
assay of sample fluids may be either monoclonal or polyclonal, and
may be prepared in any mammal.
[0090] It is usually necessary to recover or purify the protein of
interest from recombinant cell proteins or polypeptides to obtain
preparations that are substantially homogeneous. As a first step,
the culture medium or lysate may be centrifuged to remove
particulate cell debris. The protein of interest thereafter is
purified from contaminant soluble proteins and polypeptides, with
the following procedures being exemplary of suitable purification
procedures: by fractionation on an ion-exchange column; ethanol
precipitation; reverse phase HPLC; chromatography on silica or on a
cation-exchange resin such as DEAE; chromatography on protein A
Sepharose columns, chromatofocusing; SDS-PAGE; ammonium sulfate
precipitation; and gel filtration using, for example, Sephadex
G-75.
[0091] The recovered or purified protein of interest will typically
be analyzed by one or more of the following methods:
SDS-polyacrylamide gel electrophoresis, HPLC, mass spectrometry of
a tryptic digest, glycoprotein analysis and activity assays.
[0092] The following examples are offered for illustrative purposes
only, and are not intended to limit the scope of the present
invention in any way.
[0093] All patent and literature references cited in the present
specification are hereby incorporated by reference in their
entirety.
EXAMPLES
[0094] Commercially available reagents referred to in the examples
were used according to manufacturer's instructions unless otherwise
indicated. The source of those cells identified in the following
examples, and throughout the specification, unless otherwise
indicated, is the American Type Culture Collection, Manassas,
Va.
Example 1
[0095] Apoptotic Cell Death in Bioreactors
[0096] Serum free adapted, CHO (dhfr+) cells were scaled up and
seeded at 1 million cells/ml in 2 liter bioreactors, (n=2). The
cell culture media was a serum-free DMEM/Ham F-12 based medium
containing recombinant human insulin and trace elements. Cells were
grown at 37.degree. C. with agitation set at 275 rpm. pH was kept
at 7.2 and was automatically adjusted throughout the experiment.
Bioreactors were sparged with a mixture of oxygen and air. This is
a model system that mimics the conditions during large-scale
production of therapeutic proteins.
[0097] Samples were taken every day to measure the following
parameters: cell viability, caspase activity (Clontech), DNA
fragmentation and annexin/PI binding (Chemicon). FIG. 1A shows cell
viability as determined (by Trypan blue exclusion) over the course
of 5 days. FIG. 1B shows that loss of cell viability over the 5 day
period in culture was the result of apoptosis.
Example 2
[0098] Effects of Caspase-9 Dominant Negative in CHO Cells
[0099] Expression construct: C-terminal FLAG-tagged
caspase-9-dominant negative ("caspase-9-DN") cDNA (Duan, H. et al.,
J. Biol. Chemistry, 271, 16720-16724 (1996); Pan, G. et al., J.
Biol. Chemistry, 273, 5841-5845 (1998)) was subcloned in a mpsv
splice donor as further described: 2 ug of mpsv vector (Genentech,
Inc.) was digested with 5 U of EcoRI and 5 U of BamHI (Boehringer
Mannheim) and 2 ul of buffer A (Boehringer Mannheim) in a total
volume of 20 ul for 1 hour at 37.degree. C. 2 ug of
caspase-9-DN/pcDNA3 construct was digested with 5 U of HindIII and
5 U of XbaI with 2 ul of buffer B (Boehringer Mannheim) in a total
volume of 20 ul for 1 hour at 37.degree. C. After incubation, 1 ul
of 1 mM dNTPs (Clontech) and 0.2 U of Klenow polymerase (Boehringer
Mannheim) was added to each reaction and the incubation was
continued for an additional 15 minutes at 37.degree. C.
[0100] Aliquots of each digest were analyzed by 1% agarose gel
electrophoresis. 1.2 kbp caspase-9-DN cDNA and linearized 9.7 kbp
mpsv vector were cut out of the gel and the DNA was purified using
GeneClean (Bio101, Inc.) according to the manufacturer's
instructions.
[0101] Ligation of caspase-9-DN and mpsv vector: 50 ng of vector
and 42 ng of insert were ligated in 10 ul 2X ligation buffer and 1
ul T4 DNA ligase in 20 ul total volume at room temperature for 5
minutes (Boehringer Mannheim).
[0102] Transformation: MaxEfficiency DH5alfa competent cells (Gibco
BRL) were transformed with 2 ul ligation mixture according to
manufacturer's instructions. Transformed cells were then plated on
carbenicillin containing LB plates. Colonies were randomly picked
and analyzed by restriction digest to identify a colony containing
the correct construct. Colony #30 was chosen for further work.
[0103] Transfection: E25 producing CHO DP12 cells [as designated
throughout the present application, "E25 " refers to the
transfected CHO cells expressing a humanized monoclonal antibody
against human IgE; see Presta et al., J. Immunology, 151:2623-2632
(1993)] were chosen for transfection with mpsv/caspase-9-DN and
mpsv vector. Transfection was done using LipofectAMINE Plus Reagent
(Gibco BRL) and was performed as follows:
[0104] E25 cells grown in suspension were plated on 60 mm tissue
culture dishes (1 million cells/plate) 24 hours prior to
transfection in a serum-containing medium. DNA for transfection was
quantified spectrophotometrically. Two ug of DNA was mixed with 250
ul serum-free medium and 8 ul of Plus reagent and incubated for 15
minutes at room temperature. Twelve ul of reagent were mixed with
250 ul of serum-free medium and directly added to the mixture
followed by incubation for 15 minutes at room temperature. The
medium on top of the cells was replaced with 5 ml of fresh
serum-free medium and the transfection mixture was added to the
dish. Three hours post-transfection, medium was replaced with a
serum-containing medium. 24 hours post-transfection, each
transfected dish was split into 5 dishes and a selection pressure
was applied by the addition of 5 ug/ml puromycin. Transfected
clones (resistant to puromycin) began to appear about two weeks
after transfection. Several clones were chosen for analysis of
caspase-9-DN expression by Western blotting.
[0105] Western blot analysis: Selected clones were picked and
transferred into a 24 well plate. When confluent, cells from each
well were rinsed with PBS and lysed for 3 minutes in 100 ul lysis
buffer (3% NP 40 in PBS) . The lysates were centrifuged for 3
minutes at 12,000.times.g. Supernatant was collected, mixed with an
equal volume of reducing 2.times. SDS loading buffer (Novex) and
boiled for 3 minutes. Samples were stored at -20.degree. C.
Aliquots of the lysates were subjected to a protein assay to
determine the total protein concentration using Micro BCA Protein
Assay Reagent Kit (Pierce).
[0106] Aliquots of lysates corresponding to 3 ug of total protein
were loaded on a 10% SDS Tris-glycine gel (Novex) and ran for 1 1/2
hours. Proteins were transferred to an Immobilon-P transfer
Membrane according to manufacturer's directions.
[0107] The membrane was probed with rabbit anti-caspase-9 serum
(Pharmingen) followed by HRP conjugated goat=anti-rabbit antiserum
and developed using ECL Western Blotting detection Reagent
(Amersham). Clones with high as well as low expression of
caspase-9-DN (clones 2 and 14) were selected for further
characterization. See FIG. 2.
[0108] Induction of apoptosis with staurosporine: Clones 2 and 14
expressing low and high levels of caspase-9-DN (respectively) were
adapted to growth in serum-free medium in spinners. Clones were
seeded in spinners at 1 million cells/ml and an apoptosis inducing
agent, staurosporine (Sigma), was added at 1 uM final
concentration. Aliquots of culture were analyzed for apoptosis by
several assays: annexin/PI (Chemicon) to measure the % of apoptotic
cells and by caspase-3 activity (Clontech) according to
manufacturer's instructions. See FIGS. 3 and 4.
[0109] The effect of caspase-9-DN expression on viability in 2
liter bioreactors: Serum free adapted, caspase-9-DN expressing
clones 2 and 14, a vector control and untransfected E25 cells were
scaled up and seeded at 1 million cells/ml in 2 liter bioreactors
(n=2). The cell culture media was a serum-free DMEM/Ham F-12 based
medium containing recombinant human insulin and trace elements.
Cells were grown at 37.degree. C. with agitation set at 275 rpm. pH
was kept at 7.2 and was automatically adjusted throughout the
experiment. Bioreactors were sparged with a mixture of oxygen and
air. This is a model system that mimics the conditions during
large-scale production of therapeutic proteins.
[0110] Samples were taken every day to measure the following
parameters: cell viability, cell density, apoptosis, caspase-3
activation, glucose consumption, osmolality, lactate production and
E25 titers. See FIGS. 5-8.
[0111] The results show stable expression of caspase-9-DN in CHO
cells expressing E25. The stable expression resulted in a
resistance of the cells to an apoptosis inducing agent,
staurosporine. The resistance was proportional to the expression
levels of caspase-9-DN. In the environment of a bioreactor, the
high expessing clone 14 showed dramatically prolonged viability and
viable cell count compared with the lower expressing clone 2, which
showed only a moderate prolongation of viability and viable cell
count. Prolongation of viability is reflected in the delayed onset
of caspase-3 activation in clone 14 compared with the controls.
Unexpected results were obtained in the assay for the amount of E25
antibody secreted into the medium. Although caspase-9-DN clone 14
resulted in superior prolongation of viability in the bioreactor
than clone 2, clone 14 produced less protein of interest (E25
antibody). The data suggested that high expression of apoptosis
inhibitor may not concomitantly delay cell death and increase yield
of the protein of interest.
[0112] However, in another 2 liter bioreactor assay, a cell culture
was similarly run as described above with the exception of the
following changes: (1) caspase-9-expressing clone 14 and E25
control cells were seeded at 1 million cells/ml; and (2) the medium
was a serum free, concentrated medium (used to enhance nutrient
supply in the medium) based on DMEM/Ham F-12 with insulin and trace
elements. The cell cultures were grown for 1 day at 37.degree. C.
and then temperature shifted to 33.degree. C. On the third day, the
pH of the cultures was shifted from pH 7.15 to pH 7.0, and the
cultures were fed with concentrated DMEM/Ham F-12, glucose and
protein hydrolysate medium in order to supply enough nutrients to
support optimal growth.
[0113] The results are shown in FIGS. 17 and 18. As illustrated in
the graphs, caspase-9-DN expression resulted in prolongation of
viability and increase in viable cell densities, as well as higher
titers of the protein of interest (E25 antibody) as compared to the
control. Under the conditions of fed-batch culture where nutrients
were not limiting, the data showed that prolongation of viability
and increase in viable cell densities were accompanied by a marked
increase in product titer.
Example 3
[0114] Effects of Caspase Inhibitor z-VAD-fmk on Apoptosis
[0115] CHO (dhfr+) cells grown in suspension were seeded at 1
million cells/ml in 60 mm tissue culture dishes. The cell culture
media was a serum-free DMEM/Ham F-12 based medium containing
recombinant human insulin and trace elements. Viability of the
culture on day 0 was 96%. Two plates were analyzed each day for
viability by Trypan Blue exclusion and by annexin/PI binding
(Clontech) and for viable cell density. The experiment was carried
out for 10 days. A chemical inhibitor of caspases, z-VAD-fmk
(Enzyme Systems Products) was dissolved in DMSO to make a 100 mM
(1000.times.) stock and 4 ul was added to a 60 mm dish containing 4
ml of culture. The inhibitor was added 48 hours after the start of
the experiment (prior to the onset of apoptosis) and a new aliquot
of the z-VAD-fmk inhibitor was added every 24 hours. Controls were
cultures without any addition and cultures with the addition of
DMSO only.
[0116] The results are shown in FIGS. 9-10.
[0117] The chemical compound, z-VAD-fmk, is a caspase inhibitor and
when added to the culture at 100 uM concentration, resulted in an
inhibition of caspase-3 activity and prolongation of cell
viability.
Example 4
[0118] Expression of Baculovirus p35 in CHO Cells
[0119] Expression construct: The baculovirus p35 cDNA (Beidler, D.
et al., J.Biol.Chemistry, 270,16526-16528 (1995); Clem, R. J. et
al., Science, 254, 1388-1390 (1991)) was subcloned from a pcDNA3
vector (Invitrogen) into a CPC splice donor vector as follows: 2 ug
of CPC vector (Genentech, Inc.) was linearized by digestion in 25
ul containing 7 U of EcoRI and 7 U of XbaI in High buffer
(Boehringer Mannheim) for 2 hours at 37.degree. C. Baculovirus p35
cDNA was cut out of the pcDNA 3 vector (Invitrogen) with the same
restriction enzymes. An aliquot of each reaction was analyzed by
electrophoresis in 1% agarose gel containing ethidium bromide.
Bands corresponding to the linearized CPC vector (9.7 kbp) and p35
cDNA (0.9 kbp) were cut out of the gel and isolated using GeneClean
(Bio 101, Inc.) according to manufacturer's instructions.
[0120] Ligation: 50 ng of vector and 25 ng of p35 cDNA were mixed
with 10 ul of T4 ligation buffer and 1 ul T4 DNA ligase (Rapid DNA
Ligation Kit, Boehringer Mannheim) in 20 ul total reaction volume.
The reaction was incubated for 5 minutes at room temperature.
[0121] Transformation: 100 ul of Max Efficiency DH5alfa Competent
cells (Boehringer Mannheim) were mixed with 2 ul of ligation
mixture and incubated on ice for 30 minutes. Cells were
heat-shocked for 45 seconds at 42.degree. C. followed by incubation
on ice for 2 minutes. 0.9 ml of LB medium was added to the cells
and incubated for 1 hour at 37.degree. C. with agitation. 100 ul of
transformed cells were plated on LB agar plate with carbenicillin.
Four clones were randomly picked and were grown overnight in 4 ml
of LB+carbenicillin. The plasmid was isolated from these colonies
using QIAprep Spin Miniprep Kit (Qiagen) according to
manufacturer's instructions. Isolated plasmids were subjected to an
analytical digest to confirm the correct construct.
[0122] Expression of baculovirus p35 in CHO cells: CHO (dhfr+)
cells grown in a DMEM/Ham F-12 media containing 2% fetal bovine
serum (Gibco), recombinant human insulin and trace elements were
plated 48 hours prior to transfection at 2 million cells /100 m
tissue culture dish. LipofectAMINE Plus Reagent (Gibco BRL) was
used for transfection and was performed according to manufacturer's
instructions. CHO cells were transfected with a p35/CPC construct
and CPC vector alone as a control. One transfected plate of each
type was harvested 24 hours after transfection to assay the level
of p35 expression in transient transfectants (Western blotting
using anti-p35 rabbit polyclonal serum at 1:1000 dilution). Other
tranfected plates were grown further and selection pressure (5
ug/ml puromycin) was applied 48 hours post-transfection. About two
weeks later colonies resistant to puromycin developed and were
adapted to serum free growth and scaled up for further
analysis.
[0123] The effect of p35 expression on viability in 2 liter
bioreactors: The serum free adapted clone expressing p35 and a
vector control were scaled up and seeded at 1 million cells/ml in 2
liter bioreactors (n=2). The cell culture media was a serum-free
DMEM/Ham F-12 based medium containing recombinant human insulin and
trace elements. Cells were grown at 37.degree. C. with agitation
set at 275 rpm. pH was kept at 7.2 and was automatically adjusted
throughout the experiment. Bioreactors were sparged with a mixture
of oxygen and air. This is a model system that mimics the
conditions during large-scale production of therapeutic proteins.
Samples were taken every day to measure the following parameters:
cell viability, cell density, apoptosis, caspase-3 activation,
glucose consumption, osmolality and lactate production.
[0124] The results are shown in FIGS. 11-12.
[0125] The results indicate that the apoptosis inhibitor,
baculovirus p35, when expressed in CHO cells results in
prolongation of viability in the environment of the bioreactor.
Example 5
[0126] Increased Transfection Efficiency and Expression of E25
Antibody in Transient Transfections Using Caspase-9-DN
[0127] Serum free adapted CHO DP12 cells were seeded at 1.5 million
cells/ml in untreated 12 well tissue culture plates in medium based
on DMEM/HAM F-12 with modified concentrations of some components
and containing recombinant human insulin, trace elements and serum.
Transfection was performed using DMRIE-C (Gibco BRL) according to
manufacturer's instructions. Caspase-9-DN expressing clone 14 was
transfected next to controls which were CHO DP12 cells and E25
cells (CHO DP12, expressing E25).
[0128] Red shifted GFP expressing vector (Quantum Biotechnologies
Inc.) was co-transfected with a DNase expressing vector [Shak, S.
et al., (1990), Proc Natl. Acad. Sci USA, 87:9188-9192)]. 24 hours
post-transfection, propidium iodide was added to an aliquot of the
culture and total and viable transfection efficiencies were assayed
by flow cytometry on FACSCalibur (Becton Dickinson). Five days
after transfection, a sample of the medium was subjected for DNase
titer analysis using ELISA.
[0129] The data indicated (FIG. 13) that transfection reagent, in
our experiment DMRIE-C, can be toxic to cells when used at higher
concentrations (above 6 ul). In FIG. 14, caspase-9-DN clone 14
shows (in all concentrations of DMRIE-C tested) higher total and
viable transfection efficiencies than controls. The transfection
efficiency of clone 14 increased with the amount of transfection
reagent and reached maximum at 12 ul of DMRIE-C, at which
concentration both controls already started to show a decrease in
transfection efficiency. It is possible that transfection
efficiency of clone 14 will increase even further when higher than
currently tested amount of DMRIE-C is used. The increase in
transfection efficiency of clone 14 was reflected in the specific
productivity (DNase titer/total LDH) of the culture and in DNase
titer (FIGS. 15, 16), both of which were increased up to four-fold
compared with the controls.
Example 6
[0130] Effect of Caspase 9-DN Expression on Viability and Viable
Cell Number After Thawing a Frozen Culture
[0131] 2.times.10.sup.7 cells of caspase-9-DN expressing clone 14
and E25 control cells were frozen in a freezing medium (1 g/L
methylcellulose in modified DMEM/Ham F-12 and 10% DMSO) and stored
at -80.degree. C. for an extended period of time. On the day of the
experiment, vials of frozen cells were taken out of the freezer,
thawed at 37.degree. C. and added to a spinner with a pre-warmed
growth medium (modified DMEM/Ham F-12). Cells were cultured for 8
days and assayed for viability and viable cell density.
[0132] The results are shown in FIGS. 19 and 20. The results
indicate that caspase-9-DN expressing cells maintained higher
viability and viable cell count than the control E25 cells. Thus,
expression of caspase-9-DN in the CHO cells had a beneficial effect
on viability and viable cell densities upon thawing the frozen cell
cultures.
Example 7
[0133] Caspase-9-DN Expressing Cells Show Resistance to
Butyrate
[0134] The following study was conducted to examine whether
caspase-9-DN expression affects resistance of the cells to
potential adverse effects of butyrate.
[0135] Caspase-9-DN expressing clone 14 and E25 control cells were
seeded at 1.times.10.sup.6 cells/ml in 60 mm tissue culture dishes.
Each dish contained 4 ml of culture medium. Cultures were grown at
37.degree. C. in concentrated medium based on DMEM/Ham F-12 with
insulin and trace elements. Cultures were temperature shifted to
33.degree. C. on the second day and butyrate was added on the third
day at varying final concentrations (0, 1, 2, 3, 5, 10 mM) (n=2).
Viability of the cultures and titers were assayed daily.
[0136] The results are shown in FIGS. 21 and 22. The results showed
that E25 control cells lose viability more rapidly than
caspase-9-DN expressing cells (see FIG. 21, day 7 and day 9). This
is reflected in the titers of protein of interest. Titers shown in
FIG. 22 indicate that caspase-9-DN cells gave higher titers than 0
butyrate addition in cultures with 1 ,2 ,3 and 5 mM butyrate. On
the other hand, titers of E25 controls improved with only 1 and 2
mM butyrate. The results suggest that caspase-9-DN expression
protects cells from adverse effects of butyrate and can result in
extended viability and higher titers.
* * * * *